Clinical Trial

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Study acronym: IX001 TCR-T
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-21; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2025-05-24
Trial Details
NCT Number NCT06898385
Lead Sponsor Sun Yat-sen University
Collaborators: ImmuXell Biotech Ltd.
Conditions Pancreatic Cancer
Enrollment 9 participants
Start Date 2025-03-27
Primary Completion 2027-03-27 (estimated)
Study Completion 2027-09-27 (estimated)
Updated on ClinicalTrials.gov 2026-01-08